Biocon Ltd News

Biocon share falls 4% after USFDA issues VAI tag for Bengaluru's API unit

Biocon's Bengaluru API facility was inspected between September 23 to September 27, 2024

Biocon Biologics, Diabetes Africa collab over nurses project in Ethiopia

Ethiopia, with a 2-3 per cent diabetes prevalence rate, ranks among the top four countries in sub-Saharan Africa for adult diabetes cases

Bioengineering is really the way we have to move forward: Mazumdar-Shaw

Says today, we are at an inflection point when it comes to technology. Up until now, we used to scratch at the surface because we couldn't really understand the mysteries of biology

Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details

The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has classified Biocon Biologics' Biocon Park Site in Bengaluru as VAI

Biocon shares tank 6% after reporting net loss of Rs 16 cr in Q2FY25

Shares of pharmaceutical company Biocon tanked 5.96 per cent at Rs 301.65 a piece on the BSE

Biocon Q2 results: Net loss of Rs 16 cr on high tax, revenue at Rs 3,590 cr

Biocon Ltd on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024 on account of higher tax, based on geographical split of profits. The company had posted a net profit of Rs 126 crore for the July-September period last fiscal. Revenue from operations stood at Rs 3,590 crore in the September quarter as compared with Rs 3,462 crore in the year-ago period, Biocon Ltd said in a statement. "Biocon Group's overall Q2FY25 financial and operational performance provides a foundation for improved performance as we move into the second half of the fiscal," Biocon Group Chairperson Kiran Mazumdar-Shaw said. The group had a robust performance in the biosimilars business driven by strong market share gains in US Oncology and Insulin franchises, she noted. Syngene has returned to sequential growth and has good visibility of a pickup in momentum in the coming quarters led by its discovery services and biomanufacturing CMO business, she ...

Biocon inks licensing, supply pact with Tabuk Pharmaceutical Manufacturing

Biocon Ltd on Thursday said it has signed a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company to commercialise its 'GLP-1' products for treating diabetes and chronic weight management in select countries of the Middle East. Under the agreement, the company will develop and manufacture the products and Tabuk Pharmaceuticals -- a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region, will hold the marketing authorisation rights, and be responsible to register, import and promote them in the region, Biocon said in a regulatory filing. The agreement also provides for a provision to expand to other 'GLP' products, as well as the option of a tech transfer that will enable localised manufacturing at a later stage, it added. The partnership with Tabuk Pharmaceuticals paves the way for the company's vertically integrated, complex GLP1 formulations entry into Saudi Arabia and other ...

F&O Insights: Nifty pivot at 25,000; India VIX hints bullish bias building

Derivatives market update for Sept 12: Among individual stocks, Page Industries saw long buildup, while Aarti Industries and Tata Motors saw positions added on the short side of trade.

F&O Insights: Experts advocate some caution; 4 stocks in F&O ban

Derivatives market update for Sept 05: The Put-Call Ratio dropped from 0.96 to 0.82, reinforcing the dominance of call writers and a cautionary trend; 25,150 remains a key level for the Nifty, says Dh

Biocon, PFC, Chambal Fert; top picks by Ajit Mishra of Religare Broking

The pharma sector is showing notable resilience, with Biocon taking the lead. The stock has broken out from a bullish rectangle pattern, accompanied by a strong surge in volumes

Biocon subsidiary gets USFDA nod for generic drug for chronic heart failure

Biotechnology firm Biocon said its subsidiary has received approval from the US health regulator to market a generic medication to treat chronic heart failure. Biocon Pharma has received approval of its ANDA for Sacubitril/Valsartan Tablets, in 24 mg/26 mg, 49 mg/51 mg and 97 mg/103 mg strengths, from the US Food and Drug Administration (USFDA), the company said in a regulatory filing. Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalisation. The medicine is also used to treat paediatric patients over the age of one year. The approval further adds to Biocon's portfolio of vertically integrated, complex drug products, the company said.

Biocon Biologics secures deal with Janssen to launch biosimilar Bmab 1200

Agreement clears way for Indian company to launch treatment in Europe, Canada and other markets

May look to bring Liraglutide via clinical trial waiver: Mazumdar-Shaw

Kiran outlines how being vertically integrated puts Biocon in a strong position

Biocon Q1 net profit up 551%, driven by gain from Eris Life partnership

Total revenue stood at Rs 4,567 crore in Q1 FY25 as against Rs 3,516 crore in Q1 FY24

Biocon gets EMA's nod to make biosimilar cancer drug at Bengaluru

Bevacizumab is used to treat colon and rectal cancer, cervical cancer etc

Biocon searches for partner to test generic Wegovy, Ozempic in China

Biocon's generics would join at least 15 other generics or biosimilars in development by Chinese drugmakers ahead of an expiry of patent protection on semaglutide